Analysis of Revenues
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
AbbVie Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical products | |||||||||||
| Net revenues |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial performance related to pharmaceutical products and net revenues exhibits a fluctuating pattern over the five-year period. Initial growth is followed by a decline and subsequent recovery, culminating in a projected increase in the final year.
- Overall Revenue Trend
- Net revenues began at US$56,197 million in 2021, increasing to US$58,054 million in 2022, representing a growth of approximately 3.3%. A subsequent decrease was observed in 2023, with revenues falling to US$54,318 million. Revenues then partially recovered in 2024, reaching US$56,334 million, before increasing to a projected US$61,160 million in 2025.
- Pharmaceutical Product Revenue
- Revenues from pharmaceutical products mirrored the trend of net revenues. Starting at US$56,197 million in 2021, they rose to US$58,054 million in 2022. A decline followed in 2023, with revenues decreasing to US$54,318 million. A partial recovery occurred in 2024, reaching US$56,334 million, and a further increase is projected to US$61,160 million in 2025.
- Year-over-Year Changes
- The largest year-over-year increase occurred between 2024 and 2025, with a projected growth of approximately 8.5%. The most significant decline was observed between 2022 and 2023, with a decrease of approximately 6.5%. The increase from 2021 to 2022 was approximately 3.3%, and the increase from 2023 to 2024 was approximately 3.7%.
The consistency between pharmaceutical product revenues and net revenues suggests that pharmaceutical products represent the primary, if not sole, source of revenue during this period. The projected increase in 2025 indicates a potential positive shift in revenue generation.